Karger Kompass最新文献_第5页

Spektrum Pneumologie – wissenswert, kompakt, anregend 光谱肺病学》--值得了解、内容紧凑、催人奋进

Karger Kompass Pub Date : 2023-01-01 DOI: 10.1159/000533720

引用次数: 0

Prostatakarzinom: Herausforderung für die ideale Therapie 前列腺癌，理想疗法的挑战

Karger Kompass Pub Date : 2023-01-01 DOI: 10.1159/000533207

Hubert Kübler

引用次数: 0

Gesunde Haut im digitalen Zeitalter: Dermatologie im Wandel 数码时代的健康皮肤:皮肤学在改变

Karger Kompass Pub Date : 2023-01-01 DOI: 10.1159/000534837

引用次数: 0

Denke bei Vaskulitiden an das «Zebra» 在Vaskulitiden想着«斑马»

Karger Kompass Pub Date : 2023-01-01 DOI: 10.1159/000534569

Sabine Adler

引用次数: 0

Congresos y eventos 会议和活动

Karger Kompass Pub Date : 2023-01-01 DOI: 10.1159/000533980

引用次数: 0

PharmaNews 医药新闻

Karger Kompass Pub Date : 2023-01-01 DOI: 10.1159/000534722

引用次数: 0

Prurigo nodularis: Studie mit Vixarelimab zeigt vielversprechende Ergebnisse mit neuen Ansätzen nozolgo ?在vixelimab的研究中，发现了新方法有希望

Karger Kompass Pub Date : 2023-01-01 DOI: 10.1159/000534714

Nomun Ganjuur

{"title":"Prurigo nodularis: Studie mit Vixarelimab zeigt vielversprechende Ergebnisse mit neuen Ansätzen","authors":"Nomun Ganjuur","doi":"10.1159/000534714","DOIUrl":"https://doi.org/10.1159/000534714","url":null,"abstract":"Background: Prurigo nodularis is a chronic skin disease characterised by intensely pruritic, hyperkeratotic nodules. Vixarelimab, a human monoclonal antibody, binds to the beta subunit of the oncostatin M receptor, inhibiting signalling of both interleukin 31 and oncostatin M, two cytokine pathways that contribute to pruritus and nodule formation in prurigo nodularis. Methods: This double-blind, placebo-controlled, phase 2a trial was done at both private and academic dermatology outpatient research clinics across the United States and Canada (n = 40). Patient eligibility criteria included age 18–75 years, physician-documented diagnosis of prurigo nodularis minimum 6 months duration of prurigo nodularis, presence of at least 10 pruritic nodules approximately 0.5–2 cm in size on at least two different anatomical locations (excluding face and scalp) and involving the extremities, and presence of normal-appearing skin between nodules; atopic dermatitis as a comorbidity was exclusionary. Patients were required to have moderate-to-severe pruritus, defined as Worst Itch–Numeric Rating Scale (WI-NRS) score ≥7 at screening and LS-mean weekly WI-NRS score ≥5 for each of the 2 consecutive weeks immediately before randomisation. Participants were randomly assigned (1:1) to receive weekly subcutaneous vixarelimab 360 mg (720 mg loading dose) or placebo using stratification factors (sex and presence of atopy) and block size 4 through the IWRS system. Stratification by atopy status was based on the reported high prevalence of atopy in this population and the potential impact of atopy in the immunopathologic process in prurigo nodularis. Patients, investigators, study sponsor, and site staff were masked to study treatment. The primary efficacy endpoint was least squares (LS)-mean percent change from baseline (PCFB) at Week 8 in weekly average Worst Itch–Numeric Rating Scale (WI-NRS) score. The primary efficacy endpoint was analysed with ANCOVA including treatment as fixed effect, with baseline WI-NRS, and randomisation stratification factor as covariates. All randomised patients who had at least 1 dose of study drug or placebo were included in the Safety Analysis Set. This trial is registered at ClinicalTrials.gov, NCT03816891. Findings: Of 50 patients randomised between March 11, 2019 and January 31, 2020, 23 vixarelimab recipients and 26 placebo recipients comprised the modified intent-to-treat analysis population (baseline LS-mean [SD] WI-NRS score, 8.3 [1.05]). Outcomes at Week 8 for vixarelimab versus placebo included LS-mean PCFB in WI-NRS score, −50.6% versus −29.4% (LS-mean difference [95% CI], −21.2% [−40.82, −1.60]; p = 0.03); ≥4-point reduction in WI-NRS score, 52.2% (12/23) versus 30.8% (8/26) (p = 0.11); PN-IGA score of 0 or 1, 30.4% (7/23) versus 7.7% (2/26) (p = 0.03); LS-mean PCFB in pruritus VAS score, −54.4% versus −32.6% (p = 0.03); and LS-mean PCFB sleep loss reduction (improvement), −56.3% versus −30.0% (p = 0.02). No de","PeriodicalId":477056,"journal":{"name":"Karger Kompass","volume":"8 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135211980","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fibrotische ILDs: Hustenevaluation und körperliche Aktivität in die Untersuchung einbeziehen 纤维性ILDs:评估和身体活动

Karger Kompass Pub Date : 2023-01-01 DOI: 10.1159/000533809

Fotios Drakopanagiotakis, Andreas Günther

{"title":"Fibrotische ILDs: Hustenevaluation und körperliche Aktivität in die Untersuchung einbeziehen","authors":"Fotios Drakopanagiotakis, Andreas Günther","doi":"10.1159/000533809","DOIUrl":"https://doi.org/10.1159/000533809","url":null,"abstract":"Physical activity limitations and cough are common in patients with interstitial lung disease (ILD), potentially leading to reduced health-related quality of life. We aimed to compare physical activity and cough between patients with subjective, progressive idiopathic pulmonary fibrosis (IPF) and fibrotic non-IPF ILD. In this prospective observational study, wrist accelerometers were worn for seven consecutive days to track steps per day (SPD). Cough was evaluated using a visual analog scale (VAScough) at baseline and weekly for six months. We included 35 patients (IPF: n = 13; non-IPF: n = 22; mean ± SD age 61.8 ± 10.8 years; FVC 65.3 ± 21.7% predicted). Baseline mean ± SD SPD was 5008 ± 4234, with no differences between IPF and non-IPF ILD. At baseline, cough was reported by 94.3% patients (mean ± SD VAScough 3.3 ± 2.6). Compared to non-IPF ILD, patients with IPF had significantly higher burden of cough (p = 0.020), and experienced a greater increase in cough over six months (p = 0.009). Patients who died or underwent lung transplantation (n = 5), had significantly lower SPD (p = 0.007) and higher VAScough (p = 0.047). Long-term follow up identified VAScough (HR: 1.387; 95%-CI 1.081–1.781; p = 0.010) and SPD (per 1000 SPD: HR 0.606; 95%-CI: 0.412–0.892; p = 0.011) as significant predictors for transplant-free survival. In conclusion, although activity didn’t differ between IPF and non-IPF ILD, cough burden was significantly greater in IPF. SPD and VAScough differed significantly in patients who subsequently experienced disease progression and were associated with long-term transplant-free survival, calling for better acknowledgement of both parameters in disease management.","PeriodicalId":477056,"journal":{"name":"Karger Kompass","volume":"114 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136207440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

COPD: Die Eosinophilenzahl im Blut kann bei der Vorhersage künftiger Exazerbationen hilfreich sein COPD:血液中的如梦论数有助于预测未来的出访

Karger Kompass Pub Date : 2023-01-01 DOI: 10.1159/000533640

Askin Gülsen

{"title":"COPD: Die Eosinophilenzahl im Blut kann bei der Vorhersage künftiger Exazerbationen hilfreich sein","authors":"Askin Gülsen","doi":"10.1159/000533640","DOIUrl":"https://doi.org/10.1159/000533640","url":null,"abstract":"Introduction: Chronic obstructive pulmonary disease (COPD) is the third leading cause of death, and COPD exacerbation worsens the prognosis. Eosinophilic airway inflammation is a COPD phenotype that causes COPD exacerbation and is correlated with peripheral blood eosinophil count. We analyzed real-world data of COPD patients to assess the risk factors of COPD exacerbation focusing on blood eosinophils. Materials and methods: Patients with COPD who visited our hospital between January 1, 2018, and December 31, 2018, were recruited, and their background information, spirometry data, laboratory test results, and moderate-to-severe exacerbation events during the one-year follow-up period were collected from the electronic medical records and analyzed. The COPD exacerbation risk factors were assessed using univariate and multivariate logistic regression analyses. Results: Twenty-two of 271 (8.1%) patients experienced moderate-to-severe exacerbation. Patients with exacerbation showed worse pulmonary function, and we found that a high blood eosinophil count (≥350 cells/μL; p = 0.014), low % FEV1 (&#x3c;50%; p = 0.002), increase in white blood cell (≥9000 cells/μL; p = 0.039), and use of home oxygen therapy (p = 0.005) were risk factors for future exacerbations. We also found a strong correlation between eosinophil count cut-offs and exacerbation risk (r = 0.89, p &#x3c; 0.001). On the other hand, there was no relation between exacerbation risk and inhalation therapy for COPD.","PeriodicalId":477056,"journal":{"name":"Karger Kompass","volume":"19 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136207443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Wirksamkeit von Dupilumab bei chronischer Prurigo bei älteren Patienten mit atopischer Dermatitis 慢性哮喘病人对慢性哮喘的疗效

Karger Kompass Pub Date : 2023-01-01 DOI: 10.1159/000534301

Shinji Mitsuyama, Tetsuya Higuchi

引用次数: 0